CyDex, Inc., an innovator in drug delivery technologies, announced the fact that it has entered into a limited use agreement with Gilead Sciences, Inc. for CyDex's advanced formulation system Captisol.

Captisol enables the safe, effective delivery of medications by improving the solubility, stability and bioavailability of drug compounds. Captisol is a donut-shaped molecule that complexes water insoluble active drugs in its central cavity. When given by injection, Captisol-Enabled formulation helps carry a drug into the patient's bloodstream, where Captisol and the drug dissociate, allowing the active ingredient to produce its desired pharmacological effect. In oral formulations, Captisol can improve bioavailability by improving dissolution and solubility of drug compounds.